Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß.
Hurtado-Guerrero I, Pinto-Medel MJ, Urbaneja P, Rodriguez-Bada JL, León A, Guerrero M, Fernández Ó, Leyva L, Oliver-Martos B. Hurtado-Guerrero I, et al. PLoS One. 2017 Jan 19;12(1):e0170031. doi: 10.1371/journal.pone.0170031. eCollection 2017. PLoS One. 2017. PMID: 28103257 Free PMC article.
Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients.
García-León JA, Pinto-Medel MJ, García-Trujillo L, López-Gómez C, Oliver-Martos B, Prat-Arrojo I, Marín-Bañasco C, Suardíaz-García M, Maldonado-Sanchez R, Fernández-Fernández O, Leyva-Fernández L. García-León JA, et al. Mol Immunol. 2011 Sep;48(15-16):1896-902. doi: 10.1016/j.molimm.2011.05.018. Epub 2011 Jun 12. Mol Immunol. 2011. PMID: 21665278
TRAIL/TRAIL receptor system and susceptibility to multiple sclerosis.
López-Gómez C, Fernández O, García-León JA, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, Suardíaz M, García-Trujillo L, Guijarro-Castro C, Benito-León J, Prat I, Varadé J, Álvarez-Lafuente R, Urcelay E, Leyva L. López-Gómez C, et al. PLoS One. 2011;6(7):e21766. doi: 10.1371/journal.pone.0021766. Epub 2011 Jul 21. PLoS One. 2011. PMID: 21814551 Free PMC article.
ANKRD55 and DHCR7 are novel multiple sclerosis risk loci.
Alloza I, Otaegui D, de Lapuente AL, Antigüedad A, Varadé J, Núñez C, Arroyo R, Urcelay E, Fernandez O, Leyva L, Fedetz M, Izquierdo G, Lucas M, Oliver-Martos B, Alcina A, Saiz A, Blanco Y, Comabella M, Montalban X, Olascoaga J, Matesanz F, Vandenbroeck K. Alloza I, et al. Genes Immun. 2012 Apr;13(3):253-7. doi: 10.1038/gene.2011.81. Epub 2011 Dec 1. Genes Immun. 2012. PMID: 22130326
Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.
López-Gómez C, Pino-Ángeles A, Órpez-Zafra T, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, Arnáiz C, Guijarro-Castro C, Varadé J, Álvarez-Lafuente R, Urcelay E, Sánchez-Jiménez F, Fernández Ó, Leyva L. López-Gómez C, et al. PLoS One. 2013 Apr 29;8(4):e62540. doi: 10.1371/journal.pone.0062540. Print 2013. PLoS One. 2013. PMID: 23658636 Free PMC article.
Early development of anti-natalizumab antibodies in MS patients.
Oliver-Martos B, Órpez-Zafra T, Urbaneja P, Maldonado-Sanchez R, Leyva L, Fernández O. Oliver-Martos B, et al. J Neurol. 2013 Sep;260(9):2343-7. doi: 10.1007/s00415-013-6991-2. Epub 2013 Jun 14. J Neurol. 2013. PMID: 23765090 Clinical Trial.
35 results